Screener
Krystal Biotech, Inc. KRYS Total Revenue
Total Revenue at other companies
Segments
By geography
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands, except per share data) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Product revenue, net | $116,357 | $88,183 |
| Operating expenses | ||
| Cost of goods sold | 6,323 | 5,028 |
| Research and development | 15,331 | 14,256 |
| Selling, general and administrative | 41,014 | 32,647 |
| Total operating expenses | 62,668 | 51,931 |
| Income from operations | 53,689 | 36,252 |
| Other income |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s total revenue?
- Krystal Biotech, Inc. (KRYS) reported total revenue of $116.36M in Q1 2026.
- How has Krystal Biotech, Inc.'s total revenue changed year-over-year?
- Krystal Biotech, Inc.'s total revenue increased by 31.9% year-over-year, from $88.18M to $116.36M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Krystal Biotech, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude